World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
57
Citations
20694
World Ranking
10914
National Ranking
616

Daniel F. Veber publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where Daniel F. Veber sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 195 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

Daniel F. Veber D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel F. Veber sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 57 D-Index — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

Daniel F. Veber is affiliated with GlaxoSmithKline in the United Kingdom. Their professional involvement is primarily situated within the pharmaceutical industry, focusing on areas relevant to GlaxoSmithKline's research and development efforts.

There are no documented recent papers, frequent co-authors, or specific publication venues linked to Daniel F. Veber. Similarly, information about book publications, main fields of study, subfields of study, or main topics of research work is not available.

This profile is based on the accessible data regarding professional affiliation, without additional bibliometric or thematic details on scientific contributions or collaborative networks.

Best Publications

  • Molecular properties that influence the oral bioavailability of drug candidates.

    Daniel F. Veber;Stephen R. Johnson;Hung-Yuan Cheng;Brian R. Smith

  • A potent cyclic hexapeptide analogue of somatostatin

    Veber Df;Freidlinger Rm;Perlow Ds;Paleveda Wj

  • Benzodiazepine gastrin and brain cholecystokinin receptor ligands; L-365,260

    Mark G. Bock;Robert M. DiPardo;Ben E. Evans;Kenneth E. Rittle

  • Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin

    Ben E. Evans;Mark G. Bock;Kenneth E. Rittle;Robert M. Dipardo

  • Compounds and methods

    Joseph P. Marino;Scott K. Thompson;Daniel Frank Veber

  • Acetamidomethyl. A Novel Thiol Protecting Group for Cysteine

    Daniel Veber;John Milkowski;Sandor Varga;Robert Denkewalter

  • Protected lactam-bridged dipeptides for use as conformational constraints in peptides

    Roger M. Freidinger;Debra Schwenk Perlow;Daniel F. Veber

  • Peptide Aldehyde Inhibitors of Cathepsin K Inhibit Bone Resorption Both In Vitro and In Vivo

    Bartholomew J. Votta;Mark A. Levy;Alison Badger;Jeremy Bradbeer

  • Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog.

    Unknown

  • Novel renin inhibitors containing the amino acid statine

    Joshua Boger;Nancy S. Lohr;Edgar H. Ulm;Martin Poe

  • 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.

    Lara S. Kallander;Qing Lu;Wenfang Chen;Thaddeus Tomaszek

  • Conformationally restricted bicyclic analogs of somatostatin.

    Daniel F. Veber;Frederick W. Holly;William J. Paleveda;Ruth F. Nutt

  • Highly active cyclic and bicyclic somatostatin analogues of reduced ring size

    Unknown

  • A stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and .gamma.-(aminoalkyl)-.gamma.-lactones

    Ben E. Evans;Kenneth E. Rittle;Carl F. Homnick;James P. Springer

  • Design of potent and selective human cathepsin K inhibitors that span the active site

    S K Thompson;S M Halbert;M J Bossard;T A Tomaszek

  • Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.

    George B. Stroup;Michael W. Lark;Daniel F. Veber;Amit Bhattacharyya

  • Studies on the total synthesis of an enzyme. V. The preparation of enzymatically active material.

    Ralph Hirschmann;Ruth F. Nutt;Daniel F. Veber;Ronald A. Vitali

  • Protodetachable Arylsilane Polymer Linkages for Use in Solid Phase Organic Synthesis

    Joseph A. Finkelstein;Balan Chenera;Daniel F. Veber

  • Practical synthesis of cyclic peptides, with an example of dependence of cyclization yield upon linear sequence

    Stephen F. Brady;Sandor L. Varga;Roger M. Freidinger;Debra A. Schwenk

  • A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys

    S. Kumar;L. Dare;J.A. Vasko-Moser;I.E. James

  • Chemical synthesis of echistatin, a potent inhibitor of platelet aggregation from Echis carinatus: synthesis and biological activity of selected analogs.

    Victor M. Garsky;Patricia K. Lumma;Roger M. Freidinger;Steven M. Pitzenberger

  • The Controlled Synthesis of Peptides in Aqueous Medium. I. The Use of α-Amino Acid N-Carboxyanhydrides

    Robert G. Denkewalter;H. Schwam;R. G. Strachan;Thomas E. Beesley

Frequent Co-Authors

Ralph Hirschmann
Ralph Hirschmann University of Pennsylvania
Cheryl A. Janson
Cheryl A. Janson Roche (Switzerland)
Byron H. Arison
Byron H. Arison MSD (United States)
Steven A. Carr
Steven A. Carr Broad Institute
George P. Vlasuk
George P. Vlasuk Navitor Pharmaceuticals
Amy A. Sarjeant
Amy A. Sarjeant Bristol Myers Squibb
Raymond Baker
Raymond Baker MSD (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Chemistry in the USA opens doors to various exciting career paths, many of which can be pursued through specialized online degrees. For those interested in the pharmaceutical industry, understanding the pharmaceutical sales rep salary and career prospects is crucial. This role combines scientific knowledge with strong communication skills to promote medical products effectively.

Becoming a healthcare professional, such as a pharmacist, requires even more dedication. The path involves extensive education, and knowing how much schooling to be a pharmacist can help students plan their academic journey accordingly.

For those intrigued by forensic science, a career as a forensic autopsy technician can be both impactful and rewarding. Learning about the role's responsibilities and salary expectations will aid in making informed decisions. Explore the details on being a forensic autopsy technician.

Additionally, students seeking affordable education options should consider the cheapest online forensic science degree programs. These programs provide a cost-effective way to enter the rapidly growing field of forensic science with flexibility.

Best Scientists Citing Daniel F. Veber

Recently Published Articles